One-year multicentre outcomes of transapical aortic valve implantation using the SAPIEN XT valve: the PREVAIL transapical study
Key result
Transapical aortic valve implantation using the SAPIEN XT valve in high-risk patients demonstrated a 30-day survival of 91.3% and a 1-year survival of 77.9%.
Population
150 high-risk patients undergoing transapical aortic valve implantation, aged 81.6 ± 5.8 years, 40.7%…
Design
Cohort
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Supports transapical TAVI consideration in select high-risk patients; leaves open randomized comparisons to alternative access routes.
Study Design
Type
Observational (n=150)
Multicenter
Yes
Structured PICO
P
Population
150 high-risk patients (mean age 81.6 years, 40.7% female) undergoing transapical aortic valve implantation at 12 European sites, followed for 1 year.
E
Exposure
Transapical aortic valve implantation (TA-AVI) using second-generation SAPIEN XT valves (23, 26, and 29 mm) and ASCENDRA-II delivery system
O
Outcome
1-year outcomes including survivalhard clinical
Transapical aortic valve implantation using the SAPIEN XT valve demonstrated good 1-year survival and functional outcomes in high-risk patients.
Cite This Study
Walther et al. (2013) conducted an observational in High-risk patients requiring aortic valve implantation (n=150). Transapical aortic valve implantation using the SAPIEN XT valve was evaluated on 1-year survival. Transapical aortic valve implantation using the SAPIEN XT valve in high-risk patients demonstrated a 30-day survival of 91.3% and a 1-year survival of 77.9%.